Adverse events associated with commonly used glaucoma drugs

International Ophthalmology Clinics

Volumn 39, Issue 2, 1999, Pages 107-124

  Vogel, Roger ^a   Strahlman, Ellen ^a   Rittenhouse, Kay D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETAXOLOL; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DORZOLAMIDE; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; MIOTIC AGENT; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE; UNOPROSTONE ISOPROPYL ESTER;

ACCOMMODATION PARALYSIS; CARDIOTOXICITY; DIPLOPIA; DRUG HYPERSENSITIVITY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; MIOSIS; PIGMENT DISORDER; PRIORITY JOURNAL; PTOSIS; QUALITY OF LIFE; REVIEW; UVEITIS;

ADRENERGIC AGENTS; CARBONIC ANHYDRASE INHIBITORS; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MIOTICS; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS; SYMPATHOMIMETICS;

EID: 0032948120     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199903920-00009     Document Type: Review

References (83)

1. Broadway DC, Grierson I, Hitchings RA. Adverse effects of topical antiglaucoma medications on the conjunctiva. BrJ Ophthalmol 1993;77:790-796.
2. Everitt DE, Avorn J. Systemic effects of medication used to treat glaucoma. Ann Intern Med 1990;112(2):120-125
3. Kefr CR, Hass I, Drance SM, et al. Cardiovascular effects of epinephrine and dipivalyl epinephrine applied topically to the eye in patients with glaucoma. Br J Ophthal 1982;66:109-114
4. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic beta-adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol 1994;34:795-803
5. Boger WP. Timolol: short-term "escape" and long-term "drift" [editorial]. Ann Ophthalmol 1979;11:1239
6. Brubaker RF, Gaasterland D. The effect of isoproterenol on aqueous humor formation in humans. Invest Ophthalmol Vis Sci 1984;25:357
7. Kaufman PL. Pressure-dependent outflow. In: Ritch R, Shields MB, Krupin T, eds. The glaucomas, ed 2. St Louis: Mosby, 1996:307-311
8. Wang W, Sasaki H, Chien D-S, Lee VHL. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr Eye Res 1991;10:571-579
9. Olin BR ed. Drug facts and comparisons. St. Louis, JB Lippincott, 1993:1576
10. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. Br J Ophthalmol 1967;51:222-226
11. James M. Pharmacologic effects of beta-blocking agents used in the management of glaucoma [summary]. Surv Ophthalmol 1989;33:453-454
12. Brooks AMV, Gillies WE. Ocular beta-blockers in glaucoma management: clinical pharmacological aspects. Drugs Aging 1992;2:208-221
13. Lee YH, Kompella UB, Lee VHL. Systemic absorption pathways of topically applied adrenergic antagonists in the pigmented rabbit. Exp Eye Res 1993;57:341-349
14. Vouri ML, Ali-Melkkila T, Kaila T, et al. Plasma and aqueous humor concentrations and systemic effects of topical betaxolol and timolol in man. Acta Ophthalmol Scand 1993;17:201-206
15. Lesar TS. Comparison of ophthalmic beta-blocking agents. Clin Pharmacol 1987; 6:451-463
16. Hoffman BB, Lefkowitz RJ. Adrenergic receptor antagonists. In: Gilman AG, Rall TW, Niew AS, Taylor P, eds. Goodman and Gilman's the pharmacologic basis of therapeutics ed 8. New York: Pergamon Press, 1990:221-243
17. Morsman CD, Bosem ME, Lusky M, Weinreb RN. The effect of topical beta-adrenoceptor blocking agent on pulsatile ocular blood flow. Eye 1995;9:344-347
18. Neufeld AH, Zawistowski KA, Page ED, Bromberg BB. Influences on the density, of beta-adrenergic receptors in the cornea and iris-ciliary body of the rabbit. Invest Ophthalmol Vis Sci 1978;17:1069-1075
19. Gieser SC, Juzych M, Robin AL, Schwartz GF. Clinical pharmacology of adrenergic drugs. In: Ritch R, Shields MB, Krupin T, eds. The glaucomas, ed 2. St Louis: Mosby, 1996:1428-1429
20. Reyes E, Izquierdo NJ, Blasini M. Adverse drug reactions associated with glaucoma medications. Bol Asoc Med P R 1997;89:51-55
21. Odeh M, Oliven A, Bassan H. Timolol eyedrop-induced fatal bronchospasm in an asthmatic patient. J Fam Pract 1991;32:97-98
22. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. Am J Ophthalmol 1986;102:606-611
23. Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol Ther 1993;9:373-384
24. Zimmerman TJ, Leader BJ, Golob DS. Potential side effects of timolol therapy in the treatment of glaucoma. Ann Ophthalmol 1981;13:683-689
25. Grunwald JE. Effect of timolol maleate on the retinal circulation of human eyes with ocular hypertension. Invest Ophthalmol Vis Sci 1990;31:521-526
26. Coleman AL, Diehl DLC, Henry MD, et al. Topical timolol decreases plasma high-density cholesterol levels. Arch Ophthalmol 1990;108:1260-1263
27. Novack GD. Ophthalmic beta-blockers since timolol. Surv Ophthalmol 1987; 31:307-327
28. Bonomi L, Zavarise G, Noya E, Micheletto S. Effects of timolol maleate on tear flow in human eyes. Graefes Arch Klin Exp Ophthalmol 1980;213:19-22
29. Di Carlo FJ, Leinweber FJ, Szpiech JM, Davidson WF. Metabolism of 1-bunolol. Clin Pharmacol Ther 1977;22:858
30. Leinweber FJ, Greenough RC, Di Carol F. Bunolol metabolism by dogs: urinary excretion of 5-hydroxytetralone. Xenobiotica 1978;8:239-243
31. The Levobunolol Study Group. Levobunolol: a four-year study of efficacy and safety in glaucoma treatment. Ophthalmology 1989;96:642-645
32. Long D, Zimmerman T, Spaeth G, et al. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 1985;99:18-22
33. Battershill PE, Sorkin EM. Ocular metipranolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1988;36:601-615
34. Sorensen SJ, Abel SR. Comparison of the ocular beta-blockers. Ann Pharmacother 1996;30:43-54
35. Akingbehin T, Villada JR. Metipranolol-induced adverse reactions: II. Loss of intraocular pressure control. Eye 1992;6(pt 3):280-283
36. Buckley MM-T, Goa KL, Clissold SP. Ocular betaxolol: a review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 1990;40:75-90
37. Berrospi AR, Liebowitz HM. Betaxolol. A new beta-adrenergic blocking agent for the treatment of glaucoma. Arch Ophthalmol 1982;100:943-946
38. Vogel R, Tipping R, Kulaga SF, Clineschmidt CM. Changing therapy from timolol to betaxolol: effect on IOP in selected patients with glaucoma. Arch Ophthalmol 1989;107:1303-1307
39. Netland PA, Weiss HS, Stewart WC, et al. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group. Am J Ophthalmol 1997;123: 465-477
40. Chrisp P, Sorkin EM. Ocular carteolol: a review of its pharmacological properties and therapeutic use in glaucoma and ocular hypertension. Drugs Aging 1992;2:58-77
41. 2 in the cat eye. Exp Eye Res 1970;10:87
42. Bito LZ. In: Drance SM, Neufeld AH, eds. Glaucoma: applied pharmacology in medical treatment, Chap. 20. New York: Grune & Stratton, 1984:477-505
43. Alm A, Stjernschantz J, et al. Effects on IOP and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology 1995;102(12):1743-1752
44. Camras CB, et al. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. Ophthalmology 1996;103(1):138-147
45. Watson P, Stjernschantz J, et al. A six-month randomized double-masked study comparing latanoprost with timolol in open angle glaucoma and ocular hypertension. Ophthalmology 1996;103(1):126-137
46. Warwar RE, Bullock JD, Deepti B. Cystoid macular edema and anterior uveitis associated with latanoprost use. Ophthalmology 1998;105(2):263-268
47. Rowe AJ, Hattenhauser MG, Herman DC. Adverse side effects associated with latanoprost. AmJ Ophthalmol 1997;124(5):683-687
48. Watson P, et al. Latanoprost: two years' experience of its use in the United Kingdom. Ophthalmology 1998;105(1):82-87
49. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41 (suppl 2):S125-128
50. Wistrand P, Stjernschantz J, Olsson K. The incidence and time course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol 1997;41 (suppl 2):S129-138
51. Wand M. Latanoprost and hyperpigmentation of eyelashes. Arch Ophthalmol 1997;115:1206-1208
52. Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral latanoprost. Am J Ophthalmol 1997;124(4):544-547
53. Azuma I, Masuda K, Kitazawa Y, et al. Double-masked comparative study of UFO21 and timolol ophthalmic suspensions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 1993;37(4):514-525
54. Sugrue MF. The preclinical pharmacology of dorzolamide hydrochloride a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 1996;12(3):363-376
55. Kass MA, Kolker AE, Gordon M, et al. Acetazolamide and urolithiasis. Ophthalmology 1981;88:261-265
56. Weiner JM. Diuretics and other agents employed in the mobilization of edema fluid. In: Gillman AG, Rall TW, Nies AS, Taylor P, eds. The pharmacological basis of therapeutics, ed 8. New York: Macmillan, 1990:716-718
57. Hasegawa T, Hara K, Hata S. Binding of dorzolamide and its metabolite N-deethylated dorzolamide to human erythrocytes in vitro. Drug Metab Dispos 1994;22(3):377-382
58. Strahlman ER, Tipping R, Vogel R, International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol Arch Ophthalmol 1995;113:1009-1016
59. Kappil JC, Bouchard CS, Savitt ML, Kopitas E. The effect of dorzolamide on corneal thickness in pseudophakic patients. Invest Ophthalmol Vis Sci 1997;38(4):S559
60. Larsson L-I, Alm A. Aqueous humor flow in normal human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol 1998; 116:19-24
61. Hutzelman J, Polis A, Adamsons I. Comparison of tolerability and efficacy of dorzolamide and acetazolamide as adjunctive therapy to timolol. Invest Ophthalmol Vis Sci 1997;38(4):S560
62. 2 equilibra. Am J Ophthalmol 1960; 50:291-297
63. Krupin T, Oestrich CJ, Bass J. Acidosis, alkalosis and aqueous humor dynamics in rabbits Invest Ophthalmol Vis Sci 1997;16:997-1001
64. Cabin ME, Savitt ML, Kopitas EN. Comparison of serum bicarbonate levels with oral CAI versus topical dorzolamide. Invest Ophthalmol Vis Sci 1997;38(4):S560
65. Pak CYC. Pathophysiology of calcium nephrolithiasis. In: Sedin DW, Giebisch G, eds. The kidney: physiology and pathophysiology, ed 2. New York: Raven Press, 1992
66. Connor J, Keilani T, Segal R, et al. Parmacokinetics and safety of dorzolamide (MK 507) in patients with moderate renal impairment. Invest Ophthalmol Vis Sci 1995;36 (4):S738
67. Sponsel WE, Harrison J, Rowe EW, et al. Dorzolamide hydrochloride and visual function in normal eyes. Am J Ophthalmol 1997;123(6):759-766
68. Stewart R, Brinzolamide Comfort Study Group. The ocular comfort of TID-dosed brinzolamide 1.0% compared to TID-dosed dorzolamide 2.0% inpatients with primary open-angle glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci 1997;38 (4):S559
69. Robin AL, Rich R, Shin D, et al. Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. Trans Am Ophthalmol Soc 1995;93:421-438
70. Pape L, Ritch R, Papua J, Steinberger D. Long term compassionate use of apraclonidine 0.25% for refractory glaucoma [abstract]. Invest Ophthalmol Vis Sci 1992;33(4):1247
71. Cardakil F, Smythe B, Eisele J, et al. Effect of chronic apraclonidine treatment on intraocular pressure in advanced glaucoma. J Glaucoma 1994;2:271-278
72. Chung HS, Shin DH, Birt CH, et al. Chronic use of apraclonidine decreases its moderation of post-laser intraocular pressure spikes. Ophthalmology 1997;104 (11): 1921-1925
73. Nagasubramanian S, Hitchings RA, Demailly P, et al. Comparison of apraclonidine and timolol in chronic open angle glaucoma. A three month study. Ophthalmology 1993;100(9):1318-1323
74. Butler P, Mannschreck M, Lin S, et al. Clinical experience with 1% apraclonidine. Incidence of allergic reactions. Arch Ophthalmol 1995;113(3):293-296
75. Thompson CD, Macdonald TL, Garst ME, et al. Mechanism of adrenergic agonist-induced allergy bioactivation and antigen formation. Exp Eye Res 1997;64(5):767-773
76. Gross RL, Pinyero A, Orengo-Nania S. Clinical experience with apraclonidine 0.5%. J Glaucoma 1997;6(5):298-302
77. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(suppl 1):S9-18
78. Toris CB, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in the human eye. Arch Ophthalmol 1995;113:1514-1517
79. Lai RK, Chun TY, Hasson DW, et al. Brimonidine protects photoreceptors and visual function after light damage [abstract]. Invest Ophthalmol Vis Sci 1998;39(4):S876
80. Schuman JS, Horowitz B, Cholin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled randomized, multicenter clinical trial. Arch Ophthalmol 1997;115(7):847-852
81. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure; a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(suppl 1):S19-26
82. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology 1997;104(3):346
83. Gordon RN, Rich R, Liebmann JM, et al. Alpha-agonist allergy: is there cross reactivity between apraclonidine and brimonidine? Invest Ophthalmol Vis Sci 1997;38(4):S559